Article
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Cancer letters - 22 Dec 2011
Tanaka Ruriko, Kimura Shinya, Ashihara Eishi, Yoshimura Mariko, Takahashi Naoto, Wakita Hisashi, Itoh Kuniaki, Nishiwaki Kaichi, Suzuki Kenshi, Nagao Rina, Yao Hisayuki, Hayashi Yoshihiro, Satake Sakiko, Hirai Hideyo, Sawada Ken-Ichi, Ottmann Oliver G, Melo Junia V, Maekawa Taira
Abstract excerpt
ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL(+) leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.